Multi-pathogen biodefense vaccines promise broader protection, but interference can blunt performance
Multi-pathogen and combination vaccines are designed to deliver antigens from two or more pathogens in a single shot. In biodefense, that concept carries obvious appeal: one formulation could help protect against several biological threat agents at once, simplify deployment, and improve stockpiling options for emergencies where speed matters more than convenience.
The idea is straightforward. The immunology is not.
A single formulation may appear efficient on paper, yet childhood combination vaccines have long shown that immune responses do not always scale cleanly when antigens are placed together. The same concern follows biodefense vaccines, where performance against one agent cannot be allowed to erode because another antigen is present in the same product. For pathogens and toxins with high mortality, limited treatment options, or aerosol dissemination potential, even modest loss of immunogenicity can matter at the population level.
Why biodefense vaccines are being pushed toward combined formats
Biological threat agents include viruses, bacteria, and toxins that can cause severe disease and large-scale disruption. The review centers on pathogens and toxins in the U.S. Centers for Disease Control and Prevention Category A-C biodefense groupings, including filoviruses, arenaviruses, hantaviruses, flaviviruses, and bacterial or toxin threats such as Bacillus anthracis, Yersinia pestis, Francisella tularensis, and botulinum neurotoxins.
These agents share a set of difficult features: virulence, diverse transmission routes, and in many cases limited cross-protection. Ebola and Marburg viruses do not give clinicians much immunologic forgiveness across genera or species. Lassa and Machupo viruses carry reservoir and geographic complexity. Hantaviruses raise concern because aerosol transmission can make containment difficult, while arboviruses can spread through vectors across wide regions. The practical consequence is clear: biodefense planners need vaccines that can be made, stored, and deployed rapidly, and a single multi-pathogen product could reduce the burden of separate procurement and separate administration.
The attraction of a combined vaccine is logistical as much as biological. Stockpiling becomes more plausible when one formulation covers multiple outbreak scenarios. Manufacturing pipelines may also become more efficient if a single platform can be adapted to several antigens without separate product lines.
Vaccine interference centers on three recurring mechanisms
The review organizes vaccine interference into three main mechanisms: epitope competition, resource competition, and immune polarization. Each can alter how the immune system sees and processes a combined formulation.
Epitope competition occurs when antigens compete for immune recognition or processing in ways that reduce response to one component. Resource competition reflects the fact that antigen expression, cellular machinery, and immune presentation are finite. Immune polarization refers to the possibility that one vaccine component pushes the immune system toward a response pattern that is less favorable for another antigen.
Across platforms, those mechanisms do not act in the same way. Viral vectors, bacterial vectors, protein/subunit vaccines, nucleic acid platforms, and live attenuated approaches each have different vulnerabilities based on how antigen is produced, displayed, and sensed by the host. A platform that relies on host transcription and translation may face different bottlenecks than one that delivers antigen directly as a purified protein. A platform that strongly biases Th1 responses may be advantageous for some pathogens and less useful for others.
Platform choice can determine whether the combination works or fails
The review compares platform-specific risks in a way that is clinically useful for developers trying to select a backbone for biodefense vaccines. Adenovirus, vaccinia, and some bacterial vectors can face high competition for host transcriptional or translational machinery. Rhabdovirus vectors avoid transcriptional competition because they are RNA-based, but they can still face translation limits and immune-combination effects. DNA and mRNA platforms depend on cellular uptake and downstream protein production, which creates another layer of vulnerability when multiple antigens are encoded together.
Protein-based and glycoconjugate approaches avoid some of the intracellular competition seen with vector systems because they do not depend on intracellular replication or transcription. Even so, they are not immune to interference, especially if uptake, presentation, or adjuvant effects are not balanced across all antigens. Live attenuated vectors have their own constraints, particularly when antigen expression or attenuation changes the breadth and durability of the immune response.
This matters because a combined vaccine is not just a matter of attaching two antigens to the same product label. The route by which antigen enters the immune system can decide whether the formulation produces a broad antibody response, a cellular response, or an uneven mix that leaves one target underprotected.
Marburg glycoprotein is a useful stress test for combination design
The review repeatedly returns to multi-pathogen vaccines containing the Marburg virus glycoprotein antigen as a useful example of how interference can emerge. Marburg is a relevant biodefense target precisely because it is serious, difficult, and not easy to cross-protect against using generic filovirus immunity.
When Marburg glycoprotein is paired with other antigens, developers must consider whether the combination alters antigen expression, cellular processing, or the balance between B-cell and T-cell priming. If one component dominates presentation, the weaker partner may disappear immunologically even when both antigens are physically present in the same shot. In biodefense, that type of failure is not a minor formulation issue. It could leave stockpiles with a false sense of coverage.
A single antigen can crowd out another before the immune system ever gets a fair look at it.
Evaluating adverse combinations needs a clearer metric than simple co-formulation
One of the review’s central proposals is an evaluation metric for assessing potentially adverse vaccine combinations. That is a practical move. Without a structured way to compare combinations, developers are left to infer interference from scattered immunogenicity data, animal model results, and platform-specific assumptions.
The review also makes clear that the field still lacks deep experimental resolution for many combinations. Animal studies often prioritize identifying whether a candidate works at all, not why a combination performs poorly. When the goal is to advance promising candidates rather than dissect subtle failures, mechanism-specific controls may be too sparse to distinguish epitope competition from immune polarization or resource limits. The result is a literature where successful combinations are easier to recognize than explain, while poor combinations may be abandoned before the biologic reason is understood.
That gap has direct consequences for biodefense. Stockpiling strategies depend on confidence that a vaccine will perform the same way after storage, deployment, and administration under emergency conditions as it does in controlled testing. If interference is not identified early, a formulation could look attractive in development and disappoint when it is needed most.
Biodefense vaccine design will hinge on matching platform to threat biology
The review makes one broad point with unusual force: there is no universal combination strategy that fits all biodefense pathogens. Antigen biology, vector biology, and immune biology have to line up. A platform that is efficient for one pathogen pair may be a poor choice for another because of differences in epitope display, cross-presentation, B-cell accessibility, or innate immune skewing.
That reality favors platform-specific evaluation rather than assumptions borrowed from unrelated vaccines. It also argues for more explicit testing of interference mechanisms before multi-pathogen products move toward stockpiling or rapid deployment. For biodefense, the goal is not simply to make a vaccine that contains many antigens. The goal is to make one that protects against each target without sacrificing breadth, potency, or reliability in the process.
The review stops short of claiming that any one platform will solve the problem. Instead, it frames multi-pathogen vaccination as a design challenge where success will depend on understanding how antigen combinations behave inside the immune system, not just how they look in the vial.